CN1163401A - 全自动血球计数仪试剂及配制方法 - Google Patents

全自动血球计数仪试剂及配制方法 Download PDF

Info

Publication number
CN1163401A
CN1163401A CN96104706A CN96104706A CN1163401A CN 1163401 A CN1163401 A CN 1163401A CN 96104706 A CN96104706 A CN 96104706A CN 96104706 A CN96104706 A CN 96104706A CN 1163401 A CN1163401 A CN 1163401A
Authority
CN
China
Prior art keywords
reagent
nan
hpo
nacl
fully automatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96104706A
Other languages
English (en)
Inventor
李占元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from US08/789,038 external-priority patent/US5852015A/en
Publication of CN1163401A publication Critical patent/CN1163401A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

全自动血球计数仪试剂及配制方法，属医用检验试剂。目前从国外引进的全自动血球计数仪所用试剂均是国外产品，价格较高。本发明提供的试剂由盐类、缓冲试剂及表面活性剂等组成。是一种原料易得、配制简单、价格较便宜、测定结果准确，与进口试剂的精密度基本一致的全自动血球计数仪试剂。

Description

全自动血球计数仪试剂及配制方法
本发明涉及全自动血球计数仪用试剂及配制方法，属医用检验试剂。
现今医学检验技术、仪器，正由笨重的手工操作向着现代化、自动化方向发展。许多医院从国外引进的全自动血球计数仪，对提高检验工作质量和速度，缩短病人等候时间及时得到诊断和治疗起到很大作用。但是该仪器所用的试剂均是国外产品，价格较高。
本发明的目的是提供一种适用于AC-920，Cell-DYN1400、1500、1600、1700，T-540，HC-1022等型号全自动血球计数仪用试剂及其配制方法。
本发明提供的试剂由盐类、缓冲试剂及表面活性剂等组成。是一种原料易得、配制简单、价格较便宜、测定结果准确，与进口试剂的精密度基本一致的全自动血球计数仪试剂。
这种试剂包括血球稀释液(试剂A)和溶血剂(试剂B)。
1、试剂A(血球稀释液)的组成及含量：NaCl                20.2～24.5g  Na2HPO4·12H2O  42.1～45.1gNa2SO4           25.0～27.0g  NaH2PO4·2H2O   13.3～15.3gKCl                 1.5～2.0g    NaN3              1.0～1.5g
2、试剂B(溶血剂)的组成及含量：NaCl                45.0～48.1g  NaN3               0.2～0.4gNa2HPO4·12H2O  30.1～32.5g  KCN                 0.4～0.6gKCl                 1.0～1.4g    TritonX-100         5.5～6.0mlNaNO2              20.1-23.2g
配制方法：
两种试剂均加蒸镏水10L，溶解后用孔径0.2-0.4μm纤维薄膜过滤即可。
试剂配制时要严格操作，防止杂质污染，过滤时要保持清洁，以防止空白数值增高而影响测试结果的准确性。
实施例1：
试剂A(血球稀释液)：NaCl                24.5g    Na2HPO4·12H2O    45.1gNa2SO4           27.0g    NaH2PO4·2H2O     15.3gKCl                 2.0g     NaN3                 1.5g
试剂B(溶血剂)：NaCl                48.1g    NaN3                 0.4gNa2HPO4·12H2O  32.5g    KCN                   0.6gKCl                 1.4g     TritonX-100           6.0mlNaNO2              23.2g
均加蒸镏水10L，溶解后用孔径0.2μm纤维薄膜过滤。
实施例2：
试剂A(血球稀释液)：NaCl                22.5g    Na2HPO4·12H2O    43.1gNa2SO4           26.0g    NaH2PO4·2H2O     14.3gKCl                 1.7g     NaN3                1.3g
试剂B(溶血剂)：NaCl                46.1g    NaN3                0.3gNa2HPO4·12H2O  31.5g    KCN                  0.5gKCl                 1.2g     TritonX-100          5.9mlNaNO2              22.0g
均加蒸镏水10L，溶解后用孔径0.2μm纤维薄膜过滤。
实施例3：
试剂A(血球稀释液)：NaCl               20.2g     Na2HPO4·12H2O    42.1gNa2SO4          25.0g     NaH2PO4·2H2O     13.3gKCl                1.5g      NaN3                 1.0g
试剂B(溶血剂)：NaCl               45.0g     NaN3                 0.2gNa2HPO4·12H2O 30.1g     KCN                   0.4gKCl                1.0g      TritonX-100           5.8mlNaNO2             20.1g
均加蒸镏水10L，溶解后用孔径0.2μm纤维薄膜过滤。
用实施例1、2、3的试剂测定同一样品，各测20次其结果如表1：
表1
  RBC计数             WBC计数             PLT计数             Hb测定
   X   SD   CV     X   SD   CV    X     SD   CV      X     SD   CV
  实施例1   2.45   0.03   1.3％   5.68   0.20   3.6％   144     5.2   3.6％     92     1.9   2.1％
  实施例2   2.40   0.02   0.8％   5.60   0.30   5.3％   141     5.0   3.5％     90     1.8   2.0％
  实施例3   2.43   0.02   0.8％   5.70   0.30   5.3％   150     5.1   3.4％     93     2.0   2.2％
实验证明上述三种试剂测定结果基本一致。
本发明的试剂与标准品检测结果的比较：
1、测定RBC、WBC、Hb、PLT的线性关系、相关系数：
用全血质控物配制成不同浓度的样品，以末梢血测定系统进行测定见表2-5：
表2
      红细胞             RBC(×1012/L)
标准品配制浓度 1.22  2.44  3.66  4.88
用本试剂实测结果 1.25  2.45  3.67  4.76
表3
    白细胞                WBC(×1012/L)
标准品配制浓度 2.80  5.60  8.44  11.20
用本试剂实测结果 2.65  5.68  9.30  12.59
表4
    血红蛋白             Hb(g/L)
标准品配制浓度     45     90   135   180
用本试剂实测结果     45     92   140   178
表5
    血小板             PLT(×109/L)
标准品配制浓度 67.5   135   202.5   270
用本试剂实测结果 60.0   145   208.0   260
上述的相关系数：
RBC的相关系数  r＝0.9999
WBC的相关系数  r＝0.9991
Hb的相关系数   r＝0.9933
PLT的相关系数  r＝0.9937
2、用本试剂与进口试剂做白细胞分类的重复性试验。即用同一份样品，用本试剂和进口试剂分别各测20次，则得的结果如表6：
表6
               粒细胞             淋巴细胞
  X  SD   CV     X    SD     CV
进口试剂 69.9％ 0.94  1.4％   26.9％   1.41    5.2％
本试剂 69.8％ 0.94  1.3％   28.4％   1.22    4.3％
3、本试剂与进口试剂四项测定的重复性试验见表7：
表7
           RBC计数            WBC计数           PLT计数             Hb测定
   X   SD   CV    X   SD   CV    X   SD   CV    X   SD   CV
进口试剂   2.42   0.05   2.0％   5.59   0.21   3.5％   144.7     5.2   3.6％   108.8   1.96   1.8％
本试剂   2.45   0.03   1.4％   5.68   0.14   2.4％   141.4     11.6   8.2％   110.4   2.85   2.4％
综上所述，本试剂在用全血质控物(标准品)所做的线性测定，测定值与质控物值呈高度相关，有较高的准确性。本试剂与进口试剂所做的重复性试验，其变异系数均较理想，不相上下。因此本试剂在质量方面，在经济效益方面均有使用价值。

Claims (2)

1、全自动血球计数仪试剂，包括血球稀释液(试剂A)和溶血剂(试制B)，其特征在于：
试剂A的组成及含量：NaCl                20.2～24.5g   Na2HPO4·12H2O    42.1～45.1gNa2SO4            25.0～27.0g   NaH2PO4·2H2O     13.3～15.3gKCl                 1.5～2.0g     NaN3                1.0～1.5g；
试剂B的组成及含量：NaCl                45.0～48.1g   NaN3                0.2～0.4gNa2HPO4·12H2O   30.1～32.5g   KCN                  0.4～0.6gKCl                 1.0～1.4g     TritonX-100          5.5～6.0mlNaNO2              20.1-23.2g。
2、全自动血球计数仪试剂的配制方法，其特征在于：按试剂A、试剂B的组成及含量均加蒸镏水10L，溶解后用孔径0.2-0.4μm纤维薄膜过滤，即得试剂A、试剂B。
CN96104706A 1996-02-13 1996-04-19 全自动血球计数仪试剂及配制方法 Pending CN1163401A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1154296P 1996-02-13 1996-02-13
US08/789,038 US5852015A (en) 1997-01-27 1997-01-27 Triazine containing anionic compounds useful as antiviral agents

Publications (1)

Publication Number Publication Date
CN1163401A true CN1163401A (zh) 1997-10-29

Family

ID=26682512

Family Applications (2)

Application Number Title Priority Date Filing Date
CN96104706A Pending CN1163401A (zh) 1996-02-13 1996-04-19 全自动血球计数仪试剂及配制方法
CN97104706A Expired - Fee Related CN1062860C (zh) 1996-02-13 1997-02-12 用作抗病毒剂的含阴离子化合物的三嗪

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN97104706A Expired - Fee Related CN1062860C (zh) 1996-02-13 1997-02-12 用作抗病毒剂的含阴离子化合物的三嗪

Country Status (11)

Country Link
EP (1) EP0795549A1 (zh)
JP (1) JPH09309882A (zh)
KR (1) KR19980067752A (zh)
CN (2) CN1163401A (zh)
CZ (1) CZ290450B6 (zh)
HU (1) HUP9700436A1 (zh)
IL (1) IL120206A (zh)
MX (1) MXPA97001106A (zh)
NO (1) NO308469B1 (zh)
RU (1) RU2170731C2 (zh)
SK (1) SK282598B6 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1115561C (zh) * 1998-06-04 2003-07-23 梁建华 一种血液分析计数仪用稀释液和清洗液
CN101755207A (zh) * 2007-10-30 2010-06-23 松下电器产业株式会社 血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒
CN107884588A (zh) * 2017-11-13 2018-04-06 重庆艾维迪生物科技有限公司 用于检测糖化血红蛋白的溶血剂及其制备方法和应用
CN108088781A (zh) * 2016-11-23 2018-05-29 上海迈泰君奥生物技术有限公司 一种用于细胞计数仪的试剂组合

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335339B1 (en) 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
MXPA00007394A (es) * 1998-01-29 2003-08-01 Viropharma Inc Compuestos, composiciones y metodos para tratar o evitar infeccion de neumovirus y enfermedades asociadas.
US6495580B1 (en) 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
NZ517025A (en) 1999-09-24 2003-07-25 Janssen Pharmaceutica Nv Antiviral compositions
GB9928418D0 (en) * 1999-12-01 2000-01-26 Novartis Ag Organic compounds
WO2001085699A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
WO2001085700A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
US6806366B2 (en) 2001-02-02 2004-10-19 Wyeth Preparation and purification of antiviral disulfonic acid disodium salt
CA2495245A1 (en) 2002-08-09 2004-02-19 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP1545513A2 (en) 2002-08-09 2005-06-29 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
US20190209572A1 (en) * 2016-08-19 2019-07-11 Yale University Bifunctional antifungal agents and methods of treating fungal infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052988A (zh) * 1962-07-03
US3209003A (en) * 1963-06-26 1965-09-28 Sterling Drug Inc 2-amino-4-arylamino-6-(h-)-1, 3, 5-triazines
US3897430A (en) * 1973-09-24 1975-07-29 American Cyanamid Co Substituted s-triazines and method of use
DD268110A3 (de) * 1984-12-28 1989-05-24 Adl Inst Phytopathologie Mittel zur induktion von resistenz gegen viren bei kultur- und nutzpflanzen
DD298196A5 (de) * 1989-02-24 1992-02-13 Chemie Ag Bitterfeld-Wolfen,De Mittel zum schutz von kultur- und nutzpflanzen gegen viren
DK0498095T3 (da) * 1991-02-05 1995-06-19 Merrell Dow Pharma Sulfoniske stilbenderivater til behandling af virussygdomme
JPH0616561A (ja) * 1991-07-09 1994-01-25 Tsumura & Co 抗レトロウイルス剤
ATE165345T1 (de) * 1992-02-20 1998-05-15 Merrell Pharma Inc Sulfonsaeurederivate zur behandlung von viruserkrankungen

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1115561C (zh) * 1998-06-04 2003-07-23 梁建华 一种血液分析计数仪用稀释液和清洗液
CN101755207A (zh) * 2007-10-30 2010-06-23 松下电器产业株式会社 血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒
CN101755207B (zh) * 2007-10-30 2013-07-31 松下电器产业株式会社 血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒
CN108088781A (zh) * 2016-11-23 2018-05-29 上海迈泰君奥生物技术有限公司 一种用于细胞计数仪的试剂组合
CN108088781B (zh) * 2016-11-23 2020-07-21 上海迈泰君奥生物技术有限公司 一种用于细胞计数仪的试剂组合
CN107884588A (zh) * 2017-11-13 2018-04-06 重庆艾维迪生物科技有限公司 用于检测糖化血红蛋白的溶血剂及其制备方法和应用

Also Published As

Publication number Publication date
KR19980067752A (ko) 1998-10-15
MXPA97001106A (es) 2003-07-14
RU2170731C2 (ru) 2001-07-20
JPH09309882A (ja) 1997-12-02
CN1062860C (zh) 2001-03-07
NO308469B1 (no) 2000-09-18
IL120206A0 (en) 1997-06-10
EP0795549A1 (en) 1997-09-17
NO970652L (no) 1997-08-14
SK17997A3 (en) 1997-09-10
CZ42397A3 (en) 1997-10-15
IL120206A (en) 2000-02-17
SK282598B6 (sk) 2002-10-08
HUP9700436A1 (hu) 2000-08-28
HU9700436D0 (en) 1997-04-28
CN1163890A (zh) 1997-11-05
CZ290450B6 (cs) 2002-07-17
NO970652D0 (no) 1997-02-12

Similar Documents

Publication Publication Date Title
CN1163401A (zh) 全自动血球计数仪试剂及配制方法
DE69029785T2 (de) Kinetische Bestimmungsmethode für Endotoxin unter Verwendung von Limulus-Amoebocyten-Lysat und chromogenem Substrat
DE3781233T2 (de) Programm zur sicherstellung gleicher qualitaet in verschiedenen labors.
DE2553918C3 (de) Mehrzweck-Blutverdünnungsmittel
Van Sittert et al. Cytogenetic, immunological, and haematological effects in workers in an ethylene oxide manufacturing plant.
DE69527947T2 (de) Cyanidfreies reagens und verfahren zur bestimmung von hämoglobin
Aune et al. Automated flow cytometric analysis of blood cells in cerebrospinal fluid: analytic performance
CN1119657C (zh) 血液白细胞和血红蛋白浓度测定试剂
DE69624163T2 (de) In der hämatologischen Analyse von Vollblutproben verwendetes universales Reagenzspülmittel
Dimeski et al. Increased lipid concentration is associated with increased hemolysis
Kojima et al. An automated optoelectronic reticulocyte counter
Dickerhoff et al. Enumeration of platelets by multiparameter flow cytometry using platelet‐specific antibodies and fluorescent reference particles
EP0912891B1 (de) Verfahren zum durchführen von bluttests
DE69212999T2 (de) Verfahren zur Analyse der Glykierung von Hämoglobin
CN110412142A (zh) 一种检测a40926含量及有关物质的方法
CN1263266A (zh) 血液学细胞三分类全血质控物的研制
Ross et al. Neutropenia: the accuracy and precision of the neutrophil count in leukopenic patients
Sachse et al. An evaluation of the CELL‐DYN 1700® haematology analyser: automated cell counting and three‐part leucocyte differentiation
Freaney et al. Determination of ionised calcium by ion selective electrode is not independent of albumin concentration
Kraus et al. Changes in neutrophil right‐angle light scatter can occur independently of alterations in cytoskeletal actin
FI77938C (fi) Reagens foer bestaemning av antalet trombocyter och leukocyter.
Landaas et al. The Quality of Laboratory Analyses in the Primary Health Care: A Proficiency Survey on Hemoglobin, Glucose, Leucocyte Count and Sedimentation Rate (ESR) Measurements
LOHMANN et al. Profiency testing in reticulocyte counting
Mitchell et al. Effect of bias in hematofluorometer measurements of protoporphyrin in screening programs for lead poisoning.
KR100644452B1 (ko) 체액 보존제

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication